Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Deep Vein Thrombosis
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Trial Timeline
Mar 1, 2007 → Sep 1, 2009
NCT ID
NCT00423319About Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00423319. Target conditions include Deep Vein Thrombosis, Pulmonary Embolism.
What happened to similar drugs?
4 of 11 similar drugs in Deep Vein Thrombosis were approved
Approved (4) Terminated (2) Active (7)
🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00452530 | Phase 3 | Completed |
| NCT00423319 | Phase 3 | Completed |
Competing Products
20 competing products in Deep Vein Thrombosis